Can a protein calm the immune System's overreaction to cancer treatment?

NCT ID NCT04552704

Terminated Disease control Sponsor: Tianhong Li Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This early-phase trial tests whether an experimental protein called CD24Fc can help people with advanced solid tumors recover from severe immune-related side effects caused by immunotherapy. These side effects occur when the immune system attacks healthy tissues. CD24Fc is designed to dampen this overactive immune response and reduce inflammation. The study aims to see if adding CD24Fc to standard care can shorten recovery time and lessen the severity of these side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD24Fc, a lab-made protein that may calm the immune system and reduce inflammation caused by cancer immunotherapy
What this could lead to: If it works, CD24Fc could offer a faster, safer way to manage severe immune-related side effects, helping patients stay on their cancer treatment.
What could go wrong: This is an early, small trial, so results may not apply broadly. CD24Fc could also have its own side effects or fail to improve recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT SOLID NEOPLASM

Contacts and locations

Locations

University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.